Atorvastatin calcium

Atorvastatin calcium (CAS 134523-03-8), also known by the trade names Tahor and CI-981, is a pharmaceutical active ingredient used in the manufacture of cholesterol-lowering medications. It functions as an HMG-CoA reductase inhibitor and is the active salt form selected for its stability and bioavailability profile in solid dosage manufacturing for global pharmaceutical supply chains.

The primary application is in the production of oral solid dosage forms, such as tablets and film-coated tablets, for lipid management therapies where the calcium salt form supports consistent dissolution. Generic pharmaceutical manufacturers source it as the API for finished drug product registration across regulated markets including FDA, EMA, and WHO-prequalified supply chains for international distribution.

Contract development and manufacturing organizations (CDMOs) use it in formulation development projects requiring ICH-compliant starting materials to ensure high-quality therapeutic outcomes for patients. It is also sourced by quality control laboratories and reference standard suppliers for analytical method validation and comparative testing according to strict regulatory requirements and internal protocols.

Atorvastatin calcium is supplied as a white to off-white crystalline powder. It is available in anhydrous and trihydrate forms, with the trihydrate being the most commercially prevalent in manufacturing. Standard grades include USP, BP, and Ph. Eur., with documentation packages typically including CoA, DMF references, and impurity profiles aligned to pharmacopoeial specifications.